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Summary
Bariatric surgery is becoming an accepted option for obese people with type 2
diabetes. Our aim was to assess the impact of laparoscopic adjustable gastric
banding (LAGB) through a systematic review of the literature. Data was sourced
from Scopus, MEDLINE and EMBASE published from 2000 through May 2011,
and five unpublished studies that were performed by industry for regulatory
approval were also included. Studies were selected on the basis that they provide
some detail of diabetes status before and after LAGB.Therewere 35 studiesmeeting
the inclusion criteria. There was considerable heterogeneity in study design, sample
size, length of follow-up, attrition rates and classification of diabetes status.Weight
loss was progressive over the first 2 years with a weighted average of 47% excess
weight loss at 2 years. Remission or improvement in diabetes varied from 53% to
70% over different time periods. Results were broadly consistent, demonstrating
clinically relevant improvements in diabetes outcomes with sustainedweight loss in
obese people with type 2 diabetes following LAGB surgery. However, there were
significant shortcomings in the reviewed literature with few high-quality studies,
inconsistent reporting of diabetes outcomes and high attrition rates. Long-term
studies that address these limitations are needed.
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Introduction
Obesity has become a global epidemic. Currently, an esti-
mated 1.1 billion people worldwide are overweight or
obese (1). Obesity prevalence rates in several countries now
exceed 30% (2). The obesity epidemic is of particular
concern because it increases risk for several adverse health
conditions. One of the primary health hazards of obesity
is diabetes. Approximately half of those diagnosed with
type 2 diabetes are obese, and among the obese, risk for
developing diabetes increases dramatically with increasing
weight (3,4).
Although obesity is the primary cause of diabetes,
research has shown that losing as little as 5–10% of body
weight can prevent the onset of diabetes or result in
improvements or even resolution post occurrence. More-
over, larger decreases in weight generate even greater ben-
efits (5). However, large weight losses among the severely
obese population (those with a body mass index [BMI;
kg/m2] over 35) have proven difficult to sustain through
lifestyle modification. Bariatric surgery, which includes
gastric bypass surgery and gastric banding, has been shown
to be far more effective than medications and/or lifestyle
interventions at sustaining weight loss.
A meta-analysis by Buchwald et al. (6) showed that
persons with diabetes undergoing gastric bypass surgery
lost an average of 60% of excess body weight (EWL) and
that 80% of diabetes cases fully resolved. Although much
of the improvements in diabetes resolution are due to the
weight loss, there is likely to be an additional metabolic
explanation given that many patients had their glucose
levels improve even before the weight loss began to accrue
obesity reviews doi: 10.1111/j.1467-789X.2011.00928.x
57© 2011 The Authors
obesity reviews © 2011 International Association for the Study of Obesity 13, 57–67
(7,8). Gastric banding generates smaller weight losses than
gastric bypass and the improvements in diabetes status are
also slower to materialize. Yet Buchwald et al. (6) reported
that 57% of diabetes cases fully resolved with average
weight losses of 46% EWL.
Many review articles have focused on the health
improvements resulting from bariatric surgery, including
diabetes resolution rates (6,9–14). However, to date, no
review article has specifically focused on diabetes resolu-
tion rates for obese individuals with diabetes who undergo
laparoscopic adjustable gastric banding (LAGB), which is
the current standard for band placement. This article fills
that gap. We review information from prior studies and
review articles specifically related to improvements in dia-
betes status among obese individuals with diabetes who
undergo LAGB.
A current review specifically targeting improvements in
diabetes status resulting from LAGB is important given
that many obese individuals with diabetes (and many
payers) may prefer LAGB over gastric bypass surgery as
long as the potential for improvements in diabetes status
is relatively high, even if not as high as gastric bypass
surgery. This follows because banding is reversible and has
lower complication rates than gastric bypass surgery (14–
16). This study provides a single source for accessing that
information.
Methods
Literature search and inclusion criteria
We conducted a comprehensive review of recent literature
and controlled clinical studies to ascertain the effect of
LAGB on type 2 diabetes. We searched for articles in
Scopus, MEDLINE and EMBASE published from 2000
through May 2011 that included the terms ‘laparoscopic
band’ ‘lap-band’ ‘laparoscopic adjustable gastric banding’
or ‘gastric band’ in combination with ‘diabetes’. The initial
search revealed 119 studies. Bibliographic citations were
reviewed to identify additional literature for consideration.
Exclusion criteria consisted of articles that did not present
data on improvements in diabetes status post banding,
articles that only discussed gastric bypass surgery, articles
that did not include the follow-up period for which diabe-
tes improvement was reported and those in a language
other than English. Case reports and abstracts were not
included in order to avoid duplication of results with pub-
lished studies.
To be included, the studies needed to contain some
LAGB patients diagnosed with diabetes prior to surgery. In
several cases, although the overall sample was large, the
subsample of LAGB patients with diabetes at the time of
surgery was small. Moreover, in studies that enrolled
patients both with and without diabetes, enrolment, attri-
tion and weight loss outcomes were not always reported
separately for each subgroup. Therefore, for each study,
we present data on the target population, study design,
number of diabetes cases in the sample at baseline, average
age, percent female, starting BMI, length of follow-up,
attrition rates and excess weight lost from baseline (EWL)
for the diabetes sample if available or for the overall sample
if not. However, we only present improvements in diabetes
status among those patients with diabetes at baseline.
Unpublished clinical studies
In addition to our search of the existing literature, we also
included previously unpublished results from five clinical
trials conducted by Allergan both in the USA and interna-
tionally that were undertaken as part of the regulatory
review and approval process for the USA and other
countries. The five Allergan trials represent all of their
completed LAP-BAND® studies that collected diabetes
outcomes data. They are briefly summarized below. We
were unable to identify unpublished data from other band
manufacturers for inclusion.
1. LAGB-001-B was a US-based, multi-centre 1 year
study approved by the US Food and Drug Administration
(FDA) in 1998 as a continuing and expanded access study
to develop and maintain surgical skills at investigational
sites and to increase access of the LAP-BAND® for
patients. A primary objective was to assess changes in
comorbid conditions associated with obesity post surgery.
A total of 193 subjects were enrolled at 12 investigational
sites, with 15 of these subjects diagnosed with type 2 dia-
betes prior to implantation.
2. LAGB-001-C was a US-based multi-centre 1 year
study approved by the FDA in 2000 to allow obesity sur-
geons to develop LAP-BAND® surgical skills at new inves-
tigational sites and to expand access of the device to
patients while FDA review was ongoing. An additional goal
was to collect data on the band’s influence on comorbid
conditions. A total of 220 subjects were enrolled at 17
investigational sites, including 22 with type 2 diabetes diag-
nosed prior to implantation.
3. Following FDA approval in 2001, another US-based
multi-centre study, LAGB-PM-001-D, was undertaken as a
condition of approval to obtain longer term follow-up after
implantation for subjects who had been enrolled in the
pre-approval studies. A total of 109 subjects were evalu-
ated at year 3, including 17 with type 2 diabetes prior to
implantation.
4. LAGB-INT-MOB-9802 was a retrospective study at
six international sites, including Australia, France, Italy,
Mexico and two sites in Belgium. Reduction in obesity-
related comorbid conditions was one of the primary out-
comes studied. A total of 441 subjects were included in this
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retrospective study including 46 who had type 2 diabetes
prior to surgery. The LAP-BAND® surgeries were per-
formed between November 1993 and November 1998,
with primary outcomes, including changes in diabetes
status, measured at 1, 2 and 3 years post surgery.
5. LAGB-INT-MOB-9801 was a prospective data collec-
tion effort from three international investigational sites
(Australia, Italy and Mexico) on subjects implanted with
the LAP-BAND® System between November 1998 and
June 2000. As with the other international study, one of the
primary outcomes studied was reduction in comorbid con-
ditions. A total of 225 subjects were enrolled, including 32
who were diagnosed with type 2 diabetes prior to surgery.
Definitions and data presentation
The terminology used to define diabetes improvements,
which included terms such as remission, resolution or cured,
and ranges considered normal for glycosylated haemoglobin
(HbA1c) differed across studies. Therefore, consistent with
the terminology adopted by the Diabetes Surgery Summit
(International Conference on Gastrointestinal Surgery to
Treat Type 2 Diabetes, Rome, Italy,March 29–31, 2007), the
term remission was adopted to describe improvements to
normal levels among those who were considered to have
diabetes at baseline, where normal is as defined in the original
manuscript. Using this terminology, diabetes improvements
are presented as the percentage of those with diabetes at
baseline who were in remission, improved but not in remis-
sion, or who showed no change/worsening. In some cases, we
were unable to differentiate improvements from remissions.
In these cases, we conservatively placed the percentages in the
improvements column and a zero in the remission column to
ensure the totals added up to 100%. These cases are noted in
the table. Using this approach, we then combined results
across studies to present weighted average improvements at
each time period, with weights based on sample sizes of the
included studies. Based on data from those studies that report
laboratory values, we also present a separate table that
includes changes in HbA1c or fasting plasma glucose (FPG)
among the subset of cases with diabetes at baseline. For each
table, we also present weighted averages of the variables
included in the table with weights based on the number of
diabetes cases included in each study. To ease interpretation,
we present results in separate tables based on the average
length of follow-up post banding: 6 months, roughly 1 year,
15–24 months or 2–5 years.
Results
Thirty-five studies, representing 13 countries, met the
initial inclusion criteria. These studies included 23 case
series from the published literature and the five Allergan
trials that followed LAGB patients post surgery, two
retrospective data analysis of LAGB patients, four non-
randomized case-control studies that compared LAGB
patients to either non-surgical patients or to bariatric
surgery patients and one randomized controlled trial. Three
types of bands were represented in the data, including
LAP-BAND® (Allergan, Santa Barbara, CA, USA), Swedish
Band (Ethicon Endo-Surgery, Cincinnati, OH, USA) and
Easyband® (Allergan, Lausanne, Switzerland) although the
vast majority of studies reported results based on patients
who received the LAP-BAND®.
6 months
Table 1 presents results for the three studies with 6-month
assessments. All three studies were case series. For these
studies, the weighted average baseline age was 46, 76%
were female and baseline BMI was 45.0. Remission of
diabetes varied considerably across the three studies; the
weighted average rate of 62% was largely driven by the
large sample size of the Dolan et al. (17) study. Based on
the weighted average, an additional 8% showed improve-
ments in diabetes status that fell short of full remission,
while 30% saw no change or a worsening of diabetes.
Mean EWL was far more consistent, with each study
reporting a value between 25% and 31%, leading to the
overall weighted mean EWL of 30%.
12 months
Ten published studies and four Allergan studies provided
results with average follow-up of 12–13 months. The 10
published studies presented in Table 2 included seven
case series, two retrospective data analysis and one non-
randomized case-control study. For these studies, the
weighted average baseline age was 45.4, 72% were female
and average baseline BMI was 45.2. The weighted average
remission rate for diabetes was 52.3%. An additional
16.8% of diabetes cases improved but were not resolved.
At least 50% of participants showed improvements/
resolution in each of the published studies except for the
one by DeMaria et al. (23). Improvements in EWL from the
studies ranged from 22% to 62%, with a weighted average
of 34.8%. The results of the published literature were, on
average, more favourable than the results of the Allergan
trials in terms of diabetes improvements and excess weight
lost.
15–24 months
Table 3 presents the results of five published case series, two
of the unpublished Allergan studies and one published
randomized controlled trial (RCT) with follow-up data
averaging between 15 and 24months. Theweighted average
baseline age for participants in these studies was 39.4 years,
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74.2% were female and baseline BMI was 44. Rates of
diabetes remission varied between 20% and 100%,
although 4 of the 8 studies (including most of the observa-
tions) were in the 50–75% range. The weighted average
remission rate was 51%, with 4% showing improvements
that fell short of remission. Weighted average EWL was
47%, with nearly identical values in both the studies from
the literature and those from the unpublishedAllergan trials.
The RCT published byDixon et al. (32) presents results that
are more favourable than the Allergan trial data or the
non-randomized studies.
24 months follow-up
Thirteen studies, including eight published case series, two
of the Allergan studies and three non-randomized case-
control studies provided results with greater than 24
months of follow-up. These are presented in Table 4. The
weighted average baseline age for these studies was 43.9
years, 70.8% were female and baseline average BMI was
46.1. For nearly all of the published studies, the rate of
diabetes remission was between 40% and 75%. The three
exceptions that were well outside of this range had small
sample sizes. The Fielding et al. (39) study, which only had
four participants with diabetes, reported 100% remission.
Rubenstein et al. (44), which had a sample of six people
with diabetes only reported diabetes improvements, so no
remission information was available. The study by Boza
et al. (36) had 11 people with diabetes and reported an
improvement rate of 28.6%. The unpublished Allergan
trials reported slightly lower rates of diabetes remission
with rates of 34–35% though the LAGB-PM-001-D study
also reported an 18% improvement rate. Across all of the
studies, weighted averages were 37.6% for diabetes remis-
sion and 23.1% for improvements. Overall, the weighted
average EWL was 44.8%. Figure 1 displays diabetes remis-
sion and improvement rates alongside %EWL over time
from 6 months to >24 months.
Changes in clinical values
Table 5 reports improvements in clinical biochemical
values for the 10 studies that provide this information
for those with diabetes at baseline. At 6 months, Weiner
et al. (19) showed a clinically and statistically significant
improvement from a baseline mean level of 7.5 mmol L-1 to
a 6-month mean level of 5.0 mmol L-1. At 12 to 13 months,
four studies provided data on lab values related to diabetes
improvements. Dixon and O’Brien (24) showed that
HbA1c values improved from 7.8% on average at baseline
to 6.2% at 12 months. Singhal et al. (28) found smaller
improvements of HbA1c from 8.2 to 7.4% and FPG from
9.1 to 6.9 mmol L-1. Brancatisano et al. (21) found an
improvement from baseline to 12.5 months of 8.0% toTa
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6.1% and Gan et al. (25) showed an improvement from
8.9% to 7.2% from baseline to 13 months. Thus, each of
these studies showed roughly a clinically important 1.5
point improvement in HbA1c. Dixon et al. (32) found that
weight loss with LAGB lowered HbA1c from 7.8 to 6.0 at
24 months. Pontiroli et al. (43) reported a decline in
HbA1c from 9.4 to 8.0 at 36 months and Korenkov et al.
(41) reported a decline in HbA1c from 7.3 to 6.3 with
duration lasting between 36 and 96 months post surgery.
Finally, Sultan et al. had the longest follow-up of 60
months and found a decline in HbA1c from 7.53 to 6.58
and in fasting glucose from 8.1 to 6.6 mmol L-1.
Discussion
This review suggests clinically important improvements in
diabetes outcomes and sustained weight loss post LAGB.
Although rates of diabetes remission/improvement
remained high at all time points, diabetes remission rates
trended downward over time. The published data and
unpublished Allergan studies show that on average, diabe-
tes remission rates decreased from roughly 62% at 6
months to 55% at 12–24 months and finally to 38%
beyond 24 months. This downward trend is consistent with
data from the Swedish Obese Subjects study (47) and recent
reports from gastric bypass surgery (48), and indicative of
the progressive nature of type 2 diabetes. Although remis-
sion rates trended downward, when combined with diabe-
tes improvements, the longest term studies reveal remission
or improvements occurred for over 60% of LAGB patients.
The early, unpublished LAGB trials showed lower rates of
diabetes remission than the published studies, although,
due to their small sample size, combining their data with
results from the literature did not have large effects on the
overall weighted averages. The smaller remission rates may
have been due to more rigorous criteria for defining remis-
sion or the fact that physicians had limited LAGB experi-
ence. Moreover, some of these studies did not have a
classification for diabetes improvements that fell short of
remission; patients were coded as ‘in remission’ or ‘not in
remission’.
Unlike diabetes remission, EWL consistently increased
with length of follow-up for both the published studies and
80%
100%
60%
0%
20%
40%Pe
rc
en
ta
ge
6 months 12−13 months 15−24 months >24 months
Length of follow−up
Remission Remission or improvement
% EWL
Figure 1 Diabetes remission/improvement rates and %EWL at each
time point.
Table 5 Changes in diabetes lab values following LAGB
Study Length of follow-up
(months)
Lab measure Change in diabetes
lab value
% change
Weiner et al. (19) 6 FPG -3.0 mmol L-1 -40.0
Dixon and O’Brien (24) 12 HbA1c -1.6% -20.5
FPG -3.2 mmol L-1 -34.0
Singhal et al. (28) 12 HbA1c -0.8% -9.8
FPG -2.2 mmol L-1 -24.2
Brancatisano et al. (21) 12.5 HbA1c -1.9% -23.8
FPG -3.9 mmol L-1 -40.6
Gan et al. (25) 13 HbA1c -1.7% -19.1
Busetto et al. (31) 15.3 FPG -0.6 mmol L-1* -7.2%*
Dixon et al. (32) 24 HbA1c (surgery) -1.8% -23.1
HbA1c (no surgery) -0.39% -5.1
Pontiroli et al. (43) 36 HbA1c -1.4% -14.9
Korenkov et al. (41) 36–96 (average of 60) HbA1c -1.0% -13.7
Sultan et al. (46) 60 HbA1c -0.95% -12.6
FPG -1.5 mmol L-1 -18.8
*Based on overall population not diabetes population.
FPG, fasting plasma glucose; HbA1c, haemoglobin.
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for the Allergan trial data. Combined, EWL increased from
34.8% at 12 months to 47.0% at 24 months before level-
ling off at 44.8% in studies with data greater than 24
months. This is consistent with other reviews of LAGB
weight outcomes for those without diabetes (10). These
results are encouraging as those with type 2 diabetes have
been reported to have a poorer response to non-surgical
weight loss programs (49–51).
The review also revealed significant shortcomings of the
current literature. The included studies varied along many
dimensions, including study design, duration, reporting
measures, outcomes and attrition rates. Concerning attri-
tion, Tables 1–4 reveal it varied from 16.7% on average
at 12 months to 23.1% for the longest term studies.
Quality varied from a single randomized controlled trial
to retrospective cohort audits with no control groups.
Two studies included data from individuals with BMIs
less than 35 kg m-2. Although these studies are important
given the recent FDA approval to expand LAP-BAND® to
lower BMI groups, it is unclear whether these results
would generalize to those with higher BMIs (52,53).
Moreover, the majority of studies provided no biochemi-
cal evidence of glycemic control and vague or poorly
defined definitions for diabetes improvement or remission.
When in doubt, we conservatively assumed no improve-
ments; therefore, our estimates are conservative in this
regard. Although the inconsistent reporting may surprise
those familiar with managing type 2 diabetes, this is
indicative of the broader literature regarding bariatric
surgery (6). There is clearly a need for standardized ter-
minology and reporting of relevant outcome measures for
those with type 2 diabetes (54).
This review was limited to weight and diabetes out-
comes. It did not include short- or long-term complications
as this information was not available in nearly all of the
studies reviewed. However, safety of the LAGB, albeit not
specifically for those with diabetes, has been well described
in recent large cohort and registry studies (55–57). These
confirm that LAGB surgery provides the lowest post-
operative mortality, fewer complications in the first year
and the shortest hospital stay of all bariatric surgical pro-
cedures. Longer term issues such as proximal pouch dila-
tation (58), erosion of the band into the stomach (58,59)
and port and tubing issues have also been reviewed (60). In
large series, reoperation rates for all complications com-
bined are in the order of 10–15% at 5 years, and removal
of the band without replacement is roughly 5%, although
many early series had higher reoperation rates (61).
Many of the studies also had very small sample sizes for
individuals with type 2 diabetes. We account for this by
pooling data across studies and calculating weighted aver-
ages, although in some cases, data unique to those with
diabetes was not available. Moreover, because the longer
term studies may suffer from attrition bias, we cannot be
sure whether study dropouts might have shown less favour-
able weight and health outcomes. If so, our estimates
would be biased. An additional limitation is that many
studies did not report HbA1c values, so our estimates of the
effect of LAGB on improvement in HbA1c is represented
by only a subset of the included studies. Although longer
term studies that address these limitations are needed, the
studies to date provide compelling evidence that LAGB
leads to both short and longer term clinically relevant
improvements in diabetes status primarily attributed to
sustained EWL among diabetes patients who undergo the
procedure.
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